Stockscreener 앱 받기
10.01
2.72%
-0.28
시간 외 거래:
10.04
0.03
+0.30%
전일 마감가:
$10.29
열려 있는:
$10.37
하루 거래량:
4.99M
Relative Volume:
0.54
시가총액:
$1.97B
수익:
-
순이익/손실:
$-29.46M
주가수익비율:
-43.85
EPS:
-0.2283
순현금흐름:
$-28.17M
1주 성능:
-11.57%
1개월 성능:
-32.18%
6개월 성능:
+165.52%
1년 성능:
+529.56%
1일 변동 폭
$9.87
$10.54
1주일 범위
$9.19
$11.48
52주 변동 폭
$1.39
$15.88
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
명칭
Sellas Life Sciences Group Inc
전화
(646) 200-5278
주소
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
10.01 | 2.13B | 0 | -29.46M | -28.17M | -0.2283 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-07-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-01 | 개시 | Oppenheimer | Outperform |
| 2018-04-02 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 업그레이드 | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc 주식(SLS)의 최신 뉴스
SELLAS Life Sciences (NASDAQ:SLS) drops as new share count suggests $2.14 billion market cap - TechStock²
Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
SLS Stock Hits 1-Month Low On China Arbitration Blow — Retail Bulls Call It A ‘Nothingburger’ Ahead Of AML Readout - Stocktwits
3D Medicines prevails in arbitration against Sellas, awarded $1M in costs (SLS:NASDAQ) - Seeking Alpha
SLS Stock Whipsaws As Social Buzz Collides With Weak Fundamentals - timothysykes.com
SLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvals - Stocktwits
Sellas Life Sciences Group Inc (SLS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SLS Stock Pops Big After Hours On Imminent Leukemia Trial Data Readout Optimism - Stocktwits
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
SLS Stock Climbs Premarket: Here’s What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout - Stocktwits
SLS|Sellas Life Sciences Group Inc|Price:10.835|Chg%:-0.485 - TradingKey
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
Sellas Life Sciences Group Inc (SLS) Cash Flow - TradingKey
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
SLS Stock Hits Over 4-Year High: CEO Eyes FDA Talks, ‘Whole Gamut’ Of Cancer Uses For GPS - Stocktwits
SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance - Stocktwits
Sellas Life Sciences Stock (SLS) Opinions on REGAL Trial Catalysts - Moomoo
Sellas Life Sciences Group Inc (SLS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SELLAS Life Sciences shares drop 14% amid REGAL delay, challenging $2.2 billion valuation - TechStock²
SLS Stock Surges Into Conference Season As Investors Hunt For AML Readout Hints - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance - Stocktwits
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - Stocktwits
SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter - Stocktwits
SELLAS Life Sciences Group, Inc. Revenue Breakdown – LS:A2PU3T - TradingView
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - Stocktwits
SLS: SELLAS Life Sciences Group Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer - Yahoo Finance
SLS Stock Hits 4-Year High: BlackRock Stake Boost Fuels Buzz Around Looming AML Trial Readout - Stocktwits
Is SELLAS Life Sciences Group (SLS) Fully Priced As Regal Trial Debate Heats Up? - simplywall.st
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance UK
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits
SLS Stock Surges Toward Fifth Weekly Rise: CEO Touts GPS As Lifeline For Elderly Patients As Cancer Summit Looms - Stocktwits
Sellas Life Sciences Group Inc (SLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.44%
0.02%
자본화:
|
볼륨(24시간):